TY - JOUR
T1 - Adjusting glucose-stimulated insulin secretion for adipose insulin resistance
T2 - An index of β-cell function in obese adults
AU - Malin, Steven K.
AU - Kashyap, Sangeeta R.
AU - Hammel, Jeff
AU - Miyazaki, Yoshi
AU - DeFronzo, Ralph A.
AU - Kirwan, John P.
N1 - Publisher Copyright:
© 2014 by the American Diabetes Association.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - OBJECTIVE: The hyperbolic relationship between insulin secretion and sensitivity has been used to assess in vivo b-cell function (i.e., the disposition index). The disposition index emphasizes the importance of taking into account both skeletal muscle and hepatic insulin resistance to depict insulin secretion. However, we propose that adipose tissue insulin resistance also needs to be accounted for when characterizing glucose-stimulated insulin secretion (GSIS) because elevated plasma free fatty acids (FFAs) impair β-Cell function. RESEARCH DESIGN AND METHODS: To characterize the adipose disposition index, we used [1-14C] palmitate infusion to determine basal FFA turnover rate/adipose insulin resistance and an oral glucose tolerance test to characterize the first (i.e., 0-30 min) and second phase (i.e., 60 -120 min) of GSIS. We validated a simplified version of the tracer infusion calculation as the product of (1/plasma FFA concentration 3 plasma insulin concentration) 3 GSIS in 44 obese insulin-resistant subjects. RESULTS: The plasma FFA and palmitate tracer infusion calculations of the first- and second-phase disposition index were strongly correlated (r = 0.86, P < 0.000001 and r = 0.89, P < 0.000001, respectively). The first- and second-phase adipose disposition index derived from plasma FFA also was tightly associated with fasting hyperglycemia (r = 20.87, P < 0.00001 and r = 20.89, P < 0.00001, respectively) and 2-h glucose concentrations (r = 20.86, P < 0.00001 and r = 20.90, P < 0.00001). CONCLUSIONS: Adjusting GSIS for adipose insulin resistance provides an index of b-cell function in obese subjects across the glucose spectrum. Plasma FFA - derived calculations of β-cell function may provide additional insight into the role of adipose tissue in glucose regulation.
AB - OBJECTIVE: The hyperbolic relationship between insulin secretion and sensitivity has been used to assess in vivo b-cell function (i.e., the disposition index). The disposition index emphasizes the importance of taking into account both skeletal muscle and hepatic insulin resistance to depict insulin secretion. However, we propose that adipose tissue insulin resistance also needs to be accounted for when characterizing glucose-stimulated insulin secretion (GSIS) because elevated plasma free fatty acids (FFAs) impair β-Cell function. RESEARCH DESIGN AND METHODS: To characterize the adipose disposition index, we used [1-14C] palmitate infusion to determine basal FFA turnover rate/adipose insulin resistance and an oral glucose tolerance test to characterize the first (i.e., 0-30 min) and second phase (i.e., 60 -120 min) of GSIS. We validated a simplified version of the tracer infusion calculation as the product of (1/plasma FFA concentration 3 plasma insulin concentration) 3 GSIS in 44 obese insulin-resistant subjects. RESULTS: The plasma FFA and palmitate tracer infusion calculations of the first- and second-phase disposition index were strongly correlated (r = 0.86, P < 0.000001 and r = 0.89, P < 0.000001, respectively). The first- and second-phase adipose disposition index derived from plasma FFA also was tightly associated with fasting hyperglycemia (r = 20.87, P < 0.00001 and r = 20.89, P < 0.00001, respectively) and 2-h glucose concentrations (r = 20.86, P < 0.00001 and r = 20.90, P < 0.00001). CONCLUSIONS: Adjusting GSIS for adipose insulin resistance provides an index of b-cell function in obese subjects across the glucose spectrum. Plasma FFA - derived calculations of β-cell function may provide additional insight into the role of adipose tissue in glucose regulation.
UR - http://www.scopus.com/inward/record.url?scp=84910147058&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84910147058&partnerID=8YFLogxK
U2 - 10.2337/dc13-3011
DO - 10.2337/dc13-3011
M3 - Article
C2 - 25139885
AN - SCOPUS:84910147058
SN - 0149-5992
VL - 37
SP - 2940
EP - 2946
JO - Diabetes care
JF - Diabetes care
IS - 11
ER -